摘要
目的观察阿托伐他汀对颈动脉狭窄并支架置入术(CAS)后患者临床预后及炎性反应的影响。方法选择接受CAS的颈动脉狭窄患者58例,术后分为对照组28例和阿托伐他汀组30例。两组患者均常规使用低分子肝素钙、阿司匹林、氯吡格雷。阿托伐他汀组在常规用药基础上加服阿托伐他汀20毫克/次,每日1次。两组均连续用药12个月。记录所有患者治疗后12个月内支架内再狭窄事件,检测两组治疗前后血脂、超敏C反应蛋白(hs-CRP)、血清白细胞介素-6(IL-6)含量。结果服药后12个月内阿托伐他汀组支架内再狭窄事件发生率显著低于对照组(P<0.05);阿托伐他汀组血脂、血清hs-CRP、IL-6含量比治疗前及对照组显著降低(P<0.05或P<0.01);阿托伐他汀组未发现严重的不良反应。结论阿托伐他汀可减轻颈动脉狭窄并支架置入术后患者的炎性反应,减少支架内再狭窄事件发生率,且不良反应少。
Objective To observe the effect of atorvastatin on the clinical outcomes and inflammatory reaction of patients with carotid artery stenosis after stent implantation. Methods 58 patients with carotid artery stenosis who received CAS were selected. They were divided into the control group（28 patients） and the atorvastatin group （30 patients） after surgery. All patients routinely used low molecular weight heparin, aspirin and clopidogrel. Based on conventional medication, the atorvastatin group increased oral atorvastatin each 20mg, once a day. Both groups were 12 months of continuous medication. In - stent restenosis events of all patients were recorded within 12 months after treatment. The blood lipid, high sensitivity e - reactive protein （hs - CRP） , serum interleukin - 6 （IL - 6） levels were detected before and after treatment. Results The in - stent restenosis incidence rate of the atorvastatin group within 12 months was significantly lower than that of the control group after medication （P 〈 0.05 ）. Lipids, serum hs - CRP, IL - 6 levels of the atorvastatin group was significantly lower than before treatment and the control group （P 〈0.05 or P 〈 0.01 ）. The atorvastatin group found no serious adverse reactions. Conclusion Atorvastatin reduces inflammatory response in patients with carotid artery stenosis and stent implantation,reduces stent restenosis event rate, and had fewer adverse reactions.
出处
《医学研究杂志》
2010年第10期108-110,共3页
Journal of Medical Research
